Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer

Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer

Because of its low toxicity, low-dose (LD) chemotherapy is ideally suited for combination with antiangiogenic drugs. We investigated the impact of tumor vascular endothelial growth factor A (VEGF-A) expression on the efficacy of LD paclitaxel chemotherapy and its interactions with the tyrosine kinas...

Full description

Bibliographic Details
Main Authors: Holtz, David O, Krafty, Robert T, Mohamed-Hadley, Alisha, Zhang, Lin, Alagkiozidis, Ioannis, Leiby, Benjamin, Guo, Wensheng, Gimotty, Phyllis A, Coukos, George
Format: Online
Language:English
Published: BioMed Central 2008
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2235830/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2235830/

Similar Items